Answer
Bimekizumab blocks IL-17A, IL-17F and IL-17AF cytokines by selectively binding them and preventing their interaction with the IL-17RA/IL-17RC receptor complex.
Sources for this answer
- Bimzelx 160 mg solution for injection in pre-filled penUCB Pharma Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 11Document updated
Sources checked